Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
In development
Reference number: GID-TA11091
Expected publication date:
As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Acalabrutinib with bendamustine and rituximab within its marketing authorisation for untreated mantle cell lymphoma [ID6155].
Please note that following on from advice received from the company this appraisal will be rescheduled to align with latest regulatory expectations.